fluorouracil has been researched along with trimetrexate in 43 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (11.63) | 18.7374 |
| 1990's | 17 (39.53) | 18.2507 |
| 2000's | 19 (44.19) | 29.6817 |
| 2010's | 2 (4.65) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hansch, C; Khwaja, TA; Selassie, CD | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bertino, JR; Colofiore, JR; Li, WW; Romanini, A | 1 |
| Miyachi, H; Ohnuma, T; Sekiguchi, S; Takemura, Y | 1 |
| Carey, RW; Clamon, GH; Costanza, ME; Dawson, NA; Korzun, AH; Norton, L; Pollak, M; Vogelzang, NJ | 1 |
| Dykes, DJ; Elliott, WL; Howard, CT; Leopold, WR | 1 |
| Catalano, R; Comis, RL; DeLap, RJ; Grillo-Lopez, AJ; Hudes, GR; LaCreta, F | 1 |
| Bertino, JR; Nicolin, A; Romanini, A; Rosso, R; Russello, O; Sobrero, A | 1 |
| Dykes, DJ; Griswold, DP; Leopold, WR | 1 |
| Comis, RL; Hudes, GR | 1 |
| André, M; Bertino, JR; Conti, JA; Goker, E; Kemeny, N; Ragusa, K; Seiter, K; Tong, W | 1 |
| Machover, D | 1 |
| Brown, TD; Fleming, TR; Goodman, PJ; Macdonald, JS; O'Rourke, T; Pugh, RP | 1 |
| Blau, CA; Neff, T; Papayannopoulou, T | 1 |
| Blanke, CD; Capizzi, R; Kasimis, B; Kurman, M; Schein, P | 1 |
| Borud, K; Isacoff, WH | 1 |
| Bertino, JR | 2 |
| Blanke, CD; Messenger, M; Taplin, SC | 1 |
| Ardalan, B; Franceschi, D; Jaime, M; Luis, R | 1 |
| Punt, CJ | 2 |
| Henderson, CA | 1 |
| Berry, DA; Cirrincione, C; Costanza, ME; Frei, E; Henderson, IC; McIntyre, OR; Norton, L; Schilsky, RL; Weiss, RB; Winer, E; Wood, WC | 1 |
| Büchele, T; Dempke, W; Grothey, A; Schmoll, HJ | 1 |
| Berman, E; Chatterjee-Parti, S; Katzir, I; Shani, J; Wolf, W | 1 |
| Berdel, WE; Haboubi, N; Hohenberger, P; Kreuser, ED; Lochs, H; Szelényi, H; Thiel, E | 1 |
| Bowen, D; Hawkins, M; Hughes, DE; Johnson, DH; Southerland, WM | 1 |
| Blanke, CD; Carlin, D; Cox, J; Fleagle, J; Haller, D; Hammershaimb, L; Isaacs, R; Kasimis, B; Kemeny, N; Modiano, M; Moore, M; Schilsky, R; Shultz, J | 1 |
| Croles, JJ; Douma, J; Hammershaimb, L; Keizer, HJ; Lochs, H; Muller, EW; Punt, CJ; Schüller, J; Skovsgaard, T; Ten Napel, CH; Zhang, J | 1 |
| Blanke, CD; Hammershaimb, L; Punt, CJ; Zhang, J | 1 |
| Holen, KD; Saltz, LB | 1 |
| Amado, RG; Hecht, JR; Lin, LS; Rosen, LS; Rosen, PJ | 1 |
| Ando, Y; Asai, S; Kobayashi, H; Miyachi, H; Takemura, Y | 1 |
| Bologna, F; Dominguez, ME; Lacava, JA; Leone, BA; Machiavelli, MR; Ortiz, EH; Pérez, JE; Romero, AO; Salum, G; Vallejo, CT | 1 |
| Baranda, J; Garcia, AA; Leichman, CG; Leichman, L; Lenz, HJ; Pandit, L | 1 |
| Earle, M; Evans, T; Ferri, W; Friedland, D; Jacobs, SA; Matin, K; Pinkerton, R; Ramanathan, RK; Richards, T; Troetschel, M; Volkin, R; Wieand, S; Wong, MK | 1 |
| Assaraf, YG; Berman, B; Bram, E; Ifergan, I; Jansen, G; Shafran, A | 1 |
| Abbruzzese, JL; Blanke, CD; Budd, GT; Chansky, K; Christman, KL; Hundahl, SA; Issell, BF; Macdonald, JS; Van Veldhuizen, PJ | 1 |
11 review(s) available for fluorouracil and trimetrexate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The pharmacologic modulation of 5-fluorouracil with folinic acid, methotrexate, trimetrexate, and n-phosphonacetyl-l-aspartic acid (PALA). Mechanisms of the interactions and clinical data.
Topics: Aspartic Acid; Drug Interactions; Fluorouracil; Humans; Leucovorin; Methotrexate; Neoplasms; Phosphonoacetic Acid; Trimetrexate | 1994 |
Chemotherapy for the treatment of patients with metastatic colorectal cancer: an overview.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Humans; Infusions, Intravenous; Quinazolines; Thiophenes; Thymidylate Synthase; Trimetrexate | 1997 |
Biomodulation of 5-fluorouracil with antifolates.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Folic Acid Antagonists; Humans; Leucovorin; Methotrexate; Trimetrexate | 1997 |
Trimetrexate: review and current clinical experience in advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Folic Acid Antagonists; Humans; Trimetrexate | 1997 |
Biomodulation of Fluorouracil in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Clinical Trials as Topic; Colorectal Neoplasms; Drug Synergism; Fluorouracil; Humans; Interferon-alpha; Leucovorin; Methotrexate; Phosphonoacetic Acid; Trimetrexate | 1998 |
New drugs in the treatment of colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Topotecan; Trimetrexate; Uracil | 1998 |
Therapeutic options for the treatment of colorectal cancer following 5-fluorouracil failure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Cryosurgery; Embolization, Therapeutic; Fluorouracil; Hepatectomy; Humans; Infusions, Intra-Arterial; Injections, Intralesional; Irinotecan; Liver Neoplasms; Topoisomerase I Inhibitors; Treatment Failure; Trimetrexate | 1998 |
Where do we stand with 5-fluorouracil?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Chronotherapy; Colorectal Neoplasms; Dipyridamole; Drug Synergism; Fluorouracil; Humans; Interferons; Leucovorin; Levamisole; Methotrexate; Phosphonoacetic Acid; Radiation-Sensitizing Agents; Trimetrexate; Zidovudine | 1999 |
Trimetrexate as a biochemical modulator of 5-fluorouracil and leucovorin in colorectal cancer.
Topics: Antidotes; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Folic Acid Antagonists; Humans; Leucovorin; Trimetrexate | 2000 |
New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Forecasting; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Trimetrexate; Uracil | 2001 |
15 trial(s) available for fluorouracil and trimetrexate
| Article | Year |
|---|---|
Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Humans; Liver Neoplasms; Middle Aged; Quinazolines; Trimetrexate | 1991 |
Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Digestive System Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Phosphoribosyl Pyrophosphate; Survival Analysis; Treatment Outcome; Trimetrexate | 1994 |
The pharmacologic modulation of 5-fluorouracil with folinic acid, methotrexate, trimetrexate, and n-phosphonacetyl-l-aspartic acid (PALA). Mechanisms of the interactions and clinical data.
Topics: Aspartic Acid; Drug Interactions; Fluorouracil; Humans; Leucovorin; Methotrexate; Neoplasms; Phosphonoacetic Acid; Trimetrexate | 1994 |
A randomized trial of two schedules of trimetrexate versus 5-fluorouracil in advanced colorectal cancer: a Southwest Oncology Group study.
Topics: Aged; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Trimetrexate | 1995 |
Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Rectal Neoplasms; Trimetrexate | 1997 |
Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.
Topics: Adenine; Adult; Aged; Aminoglycosides; Analysis of Variance; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Imides; Isoquinolines; Melphalan; Middle Aged; Naphthalimides; Neoplasm Staging; Organophosphonates; Prospective Studies; Survival Analysis; Trimetrexate | 1999 |
Sequential trimetrexate, 5-fluorouracil and folinic acid are effective and well tolerated in metastatic colorectal carcinoma. The phase II study group of the AIO.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Survival Analysis; Treatment Outcome; Trimetrexate | 2000 |
A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Double-Blind Method; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Quality of Life; Survival Rate; Time Factors; Trimetrexate | 2002 |
Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Europe; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Quality of Life; Survival Rate; Trimetrexate | 2002 |
Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Leucovorin; Male; Survival Analysis; Survival Rate; Time Factors; Trimetrexate | 2002 |
Low-dose trimetrexate glucuronate and protracted 5-fluorouracil infusion in previously untreated patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Glucuronates; Humans; Infusions, Intravenous; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Survival Analysis; Trimetrexate | 2002 |
Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis; Treatment Failure; Trimetrexate | 2004 |
Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome; Trimetrexate; Vomiting | 2003 |
A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Trimetrexate | 2005 |
S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Survival Rate; Treatment Outcome; Trimetrexate; Young Adult | 2010 |
18 other study(ies) available for fluorouracil and trimetrexate
| Article | Year |
|---|---|
Structure-activity relationships of antineoplastic agents in multidrug resistance.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Cricetinae; Dactinomycin; Drug Resistance; Leukemia L1210; Mice; Regression Analysis; Structure-Activity Relationship; Tumor Cells, Cultured | 1990 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Fluorouracil; Humans; Leucovorin; Leukemia, Lymphoid; Methotrexate; Phosphoribosyl Pyrophosphate; Trimetrexate; Tumor Cells, Cultured | 1992 |
A human leukemia cell line made resistant to two folate analogues, trimetrexate and N10-propargyl-5,8-dideazafolic acid (CB3717).
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Division; Cell Line; Cisplatin; Cross Reactions; Dactinomycin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Etoposide; Fluorouracil; Folic Acid; Humans; Leucovorin; Membrane Glycoproteins; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Quinazolines; RNA, Messenger; Thymidylate Synthase; Trimetrexate; Vincristine | 1991 |
Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Survival; Cricetinae; Drug Administration Schedule; Drug Synergism; Fluorouracil; Folic Acid Antagonists; Leukemia P388; Mice; Phosphoribosyl Pyrophosphate; Quinazolines; Trimetrexate | 1989 |
Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Proteins; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Mouth Mucosa; Neoplasms; Neutropenia; Protein Binding; Quinazolines; Stomatitis; Thrombocytopenia; Trimetrexate | 1989 |
Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: implications for the mechanism of this interaction.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colony-Forming Units Assay; Drug Interactions; Drug Synergism; Floxuridine; Fluorouracil; Folic Acid Antagonists; Humans; Methotrexate; Quinazolines; Trimetrexate; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1989 |
Therapeutic synergy of trimetrexate (CI-898) in combination with doxorubicin, vincristine, cytoxan, 6-thioguanine, cisplatin, or 5-fluorouracil against intraperitoneally implanted P388 leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Synergism; Fluorouracil; Leukemia P388; Leukemia, Experimental; Mice; Quinazolines; Thioguanine; Trimetrexate; Vincristine | 1987 |
Phase 1 and 2 studies of trimetrexate administered in combination with fluorouracil to patients with metastatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Quinazolines; Trimetrexate | 1988 |
The hematological effects of folate analogs: implications for using the dihydrofolate reductase gene for in vivo selection.
Topics: Animals; Antimetabolites; Bone Marrow; Cells, Cultured; Femur; Fluorouracil; Genetic Therapy; Immunocompromised Host; Leukocytes, Mononuclear; Methotrexate; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Spleen; Stem Cell Factor; Tetrahydrofolate Dehydrogenase; Trimetrexate | 1996 |
Enhancement of 5-fluorouracil anabolism by methotrexate and trimetrexate in two rat solid tumor models, Walker 256 carcinosarcoma and Novikoff hepatoma, as evaluated by 19F-magnetic resonance spectroscopy.
Topics: Animals; Carcinoma 256, Walker; Drug Administration Schedule; Fluorine; Fluorouracil; Kinetics; Liver Neoplasms, Experimental; Magnetic Resonance Spectroscopy; Male; Methotrexate; Rats; Rats, Sprague-Dawley; Trimetrexate | 2000 |
Implications for improved high-dose methotrexate therapeutic effects in cultured human breast cancer and bone marrow cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Breast Neoplasms; Cell Line; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Folic Acid Antagonists; Humans; Methotrexate; Trimetrexate; Tumor Cells, Cultured | 2000 |
Modulation of 5-fluorouracil/leucovorin by trimetrexate--did it work?
Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Synergism; Fluorouracil; Humans; Leucovorin; Placebos; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome; Trimetrexate; United States; United States Food and Drug Administration | 2002 |
Large diversity in transport-mediated methotrexate resistance in human leukemia cell line CCRF-CEM established in a high concentration of leucovorin.
Topics: Amino Acid Substitution; Antimetabolites, Antineoplastic; Biological Transport; Carrier Proteins; Codon; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorouracil; Humans; Inhibitory Concentration 50; Intracellular Fluid; Leucovorin; Leukemia, T-Cell; Membrane Proteins; Membrane Transport Proteins; Methotrexate; Mutation, Missense; Neoplasm Proteins; Point Mutation; Selection, Genetic; Sequence Deletion; Tetrahydrofolate Dehydrogenase; Trimetrexate; Tumor Cells, Cultured | 2003 |
Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Cell Proliferation; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Fluorouracil; Folic Acid Antagonists; Heterocyclic Compounds, 3-Ring; Humans; Indoles; Lipids; Molecular Structure; Mutation; Neoplasm Proteins; Paclitaxel; Pyrimethamine; Pyrimidines; Quinazolines; Rhodamines; Transfection; Trimetrexate | 2006 |